In contrast, PRDM1 has been known as the tumor suppressor in the blood cancers, which was consistent in the present analyses on the survival of patients with lymphomas and myelomas (Supplementary Fig. 1B). This evidence concerns the gene PRDM1 and hematopoietic and lymphoid system neoplasm.